Dupixent (dupilumab) — Medica

Asthma

Initial criteria

age ≥ 6 years
Patient has blood eosinophil level ≥ 150 cells/μL within previous 6 weeks OR had level ≥ 150 cells/μL prior to treatment with Dupixent or another monoclonal antibody that alters eosinophils OR has oral corticosteroid-dependent asthma (≥ 5 mg prednisone equivalent per day ≥ 6 months)
Patient has received ≥ 3 consecutive months of combination therapy with an inhaled corticosteroid AND at least one additional asthma controller/maintenance medication
Asthma uncontrolled or was uncontrolled at baseline defined by ≥ 2 exacerbations requiring systemic corticosteroids in previous year OR ≥ 1 hospitalization/emergency/urgent care visit in previous year OR FEV1 < 80% predicted OR FEV1/FVC < 0.80 OR worsening with tapering oral corticosteroid
Prescribed by or in consultation with an allergist, immunologist, or pulmonologist

Patient has already received ≥ 6 months of therapy with Dupixent
Continues inhaled corticosteroid or corticosteroid-containing combination inhaler
Patient has responded to therapy as determined by prescriber (e.g., decreased exacerbations, symptoms, hospitalizations, emergency visits, or oral corticosteroid use)

initial 6 months, reauthorization 1 year